DavidWheeler United KingdomUniversity College London

David C WheelerrDavid is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinical scientist interested in chronic kidney disease (CKD). He has participated in the development and delivery of several large-scale clinical trials testing lipid lowering regimens (SHARP), calcimimetics (EVOLVE), intravenous iron (PIVOTAL), SGLT2 inhibitors (CREDENCE and DAPA-CKD) and HIF stabilisers (ASCEND) in patients with CKD. He was co-chief investigator for the DAPA-CKD study (with Hiddo Lambers Heerspink). David has been involved in the development of Clinical Practice Guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-chair between 2012 and 2019. Other recent roles include Chair of the International Society of Nephrology Advancing Clinical Trials (ISN-ACTs) committee. In the UK, he is National Institute of Health Research (NIHR) Specialty Lead for Renal Disorders.

Upload Picture

https://storage.unitedwebnetwork.com/files/1099/4ebc6caaa51e79209f4061cd08dff279.jpg

First name

David

Last name

Wheeler

Institution

Country

United Kingdom

Friday, February 7, 2025

Time	Session

2:15 p.m. 3:45 p.m.	Bridging the Clinical Gap: Sustainable Strategies and Innovative Therapies for Global Kidney Health BKH02 ErangaWijewickrama Chair Sri LankaFaculty of Medicine, University of Colombo Prof (Dr ) SanjeevGulati Chair sgulati2002@gmail.comIndiaExecutive Director Nephrology and Kidney Transplant, Fortis gp of Hospitals and Adjunct Professor, Manipal University Sustainable Community Approaches to Early CKD Detection BKH02-01 RonaldGansevoort Speaker NetherlandsDept. Nephrology, University Medical Center Groningen Kidney Disease Treatment Gaps Worldwide - Where Are the Solutions? BKH02-02 AdeeraLevin Speaker CanadaUniversity of British Columbia and Providence Health Care The Promise of Emerging Therapies in Reducing the Global Kidney Disease Burden BKH02-03 DavidWheeler Speaker United KingdomUniversity College London Co-opting Patients as Partners in Kidney Care: How Do We Do It? BKH02-04 ShilpanjaliJesudason Speaker AustraliaRoyal Adelaide Hospital and Adelaide University, Australia Co-opting Patients as Partners in Kidney Care: How Do We Do It? BKH02-05 ShyamsundarMuthuramalingam Speaker Shyamsundar.Muthuramalingam@sa.gov.auAustraliaCentral Adelaide Local Health Network Q&A BKH02-06 Kesar Hall 202

Time

Session

2:15 p.m.

3:45 p.m.

Bridging the Clinical Gap: Sustainable Strategies and Innovative Therapies for Global Kidney Health

BKH02

ErangaWijewickrama Chair Sri LankaFaculty of Medicine, University of Colombo

Prof (Dr ) SanjeevGulati Chair sgulati2002@gmail.comIndiaExecutive Director Nephrology and Kidney Transplant, Fortis gp of Hospitals and Adjunct Professor, Manipal University

Sustainable Community Approaches to Early CKD Detection

BKH02-01

RonaldGansevoort Speaker NetherlandsDept. Nephrology, University Medical Center Groningen
Kidney Disease Treatment Gaps Worldwide - Where Are the Solutions?

BKH02-02

AdeeraLevin Speaker CanadaUniversity of British Columbia and Providence Health Care
The Promise of Emerging Therapies in Reducing the Global Kidney Disease Burden

BKH02-03

DavidWheeler Speaker United KingdomUniversity College London
Co-opting Patients as Partners in Kidney Care: How Do We Do It?

BKH02-04

ShilpanjaliJesudason Speaker AustraliaRoyal Adelaide Hospital and Adelaide University, Australia
Co-opting Patients as Partners in Kidney Care: How Do We Do It?

BKH02-05

ShyamsundarMuthuramalingam Speaker Shyamsundar.Muthuramalingam@sa.gov.auAustraliaCentral Adelaide Local Health Network
Q&A

BKH02-06

Kesar Hall 202

Saturday, February 8, 2025

Time	Session

2:15 p.m. 3:45 p.m.	What’s Next in Kidney Care Research? Innovations and Clinical Trials on the Horizon SS2 AdeeraLevin Chair CanadaUniversity of British Columbia and Providence Health Care Andrea Viecelli Chair SwitzerlandUniversity Hospital of Zurich Ajit singhNarula Chair narulaas@gmail.comIndia Novel Trial Designs in Nephrology: Innovations and Structures SS2-01 MegJardine Speaker AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia What’s New in Clinical Trials? SS2-02 DavidWheeler Speaker United KingdomUniversity College London Value of Different Outcomes in the Era of Precision Medicine SS2-03 RobertoPecoits-Filho Speaker United StatesArbor Research Collaborative for Health Conducting Trials in Low and Middle-income Countries SS2-04 SoumitaBagchi Speaker soumita_bagchi@yahoo.co.inIndiaProfessor, Department of Nephrology, All India Institute of Medical Sciences, New Delhi Innovations in Pediatric Nephrology Discovery and Clinical Trial Conduct SS2-05 ArpanaIyengar Speaker IndiaST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES, BANGALORE Q&A SS2-06 Parijat Hall 201

Time

Session

2:15 p.m.

3:45 p.m.

What’s Next in Kidney Care Research? Innovations and Clinical Trials on the Horizon

SS2

AdeeraLevin Chair CanadaUniversity of British Columbia and Providence Health Care

Andrea Viecelli Chair SwitzerlandUniversity Hospital of Zurich

Ajit singhNarula Chair narulaas@gmail.comIndia

Novel Trial Designs in Nephrology: Innovations and Structures

SS2-01

MegJardine Speaker AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia
What’s New in Clinical Trials?

SS2-02

DavidWheeler Speaker United KingdomUniversity College London
Value of Different Outcomes in the Era of Precision Medicine

SS2-03

RobertoPecoits-Filho Speaker United StatesArbor Research Collaborative for Health
Conducting Trials in Low and Middle-income Countries

SS2-04

SoumitaBagchi Speaker soumita_bagchi@yahoo.co.inIndiaProfessor, Department of Nephrology, All India Institute of Medical Sciences, New Delhi
Innovations in Pediatric Nephrology Discovery and Clinical Trial Conduct

SS2-05

ArpanaIyengar Speaker IndiaST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES, BANGALORE
Q&A

SS2-06

Parijat Hall 201

Sunday, February 9, 2025

Time	Session

9 a.m. 10:30 a.m.	HIT! High Impact Clinical Trials – Why and How HIT2 DavidWheeler Chair United KingdomUniversity College London Winston Wing ShingFung Chair Hong Kong, ChinaPrince of Wales Hospital, Hong Kong What Have We Learned From CONVINCE? HIT2-1 PeterBlankestijn Oral Abstract Presenter P.J.Blankestijn@umcutrecht.nlNetherlandsUniversity Medical Center Utrecht Design of the ZEUS Trial: Interleukin-6 Inhibition With Ziltivekimab for Cardiovascular Protection in Chronic Kidney Disease HIT2-2 VladoPerkovic Oral Abstract Presenter AustraliaUniversity of New South Wales, Sydney, Australia A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN) HIT2-3 Jonathan Barratt Oral Abstract Presenter United KingdomUniversity of Leicester, Leicester, UK Observational Cohort With Embedded Randomized Controlled Trials to Study Pregnancy-Associated Progression of Renal Disease: A Feasibility Study of Dietary Nitrate (Beetroot Juice) to Protect Kidney Function in Pregnant Women With Chronic Kidney Disease HIT2-4 KateBramham Oral Abstract Presenter United KingdomKing's College London Design of Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven Primary Glomerular Diseases: Multi-Center, Multi-Arm and Multi-Stage HIT2-5 Selvin Sundar RajMani Oral Abstract Presenter IndiaAssociate Professor in Nephrology, Christian Medical College, Vellore, India SuceenaAlexander Oral Abstract Presenter IndiaChristian Medical College Vellore Brahmkamal Hall - Plenary Hall

Time

Session

9 a.m.

10:30 a.m.

HIT! High Impact Clinical Trials – Why and How

DavidWheeler Chair United KingdomUniversity College London

Winston Wing ShingFung Chair Hong Kong, ChinaPrince of Wales Hospital, Hong Kong

What Have We Learned From CONVINCE?

HIT2-1

PeterBlankestijn Oral Abstract Presenter P.J.Blankestijn@umcutrecht.nlNetherlandsUniversity Medical Center Utrecht
Design of the ZEUS Trial: Interleukin-6 Inhibition With Ziltivekimab for Cardiovascular Protection in Chronic Kidney Disease

HIT2-2

VladoPerkovic Oral Abstract Presenter AustraliaUniversity of New South Wales, Sydney, Australia
A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)

HIT2-3

Jonathan Barratt Oral Abstract Presenter United KingdomUniversity of Leicester, Leicester, UK
Observational Cohort With Embedded Randomized Controlled Trials to Study Pregnancy-Associated Progression of Renal Disease: A Feasibility Study of Dietary Nitrate (Beetroot Juice) to Protect Kidney Function in Pregnant Women With Chronic Kidney Disease

HIT2-4

KateBramham Oral Abstract Presenter United KingdomKing's College London
Design of Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven Primary Glomerular Diseases: Multi-Center, Multi-Arm and Multi-Stage

HIT2-5

Selvin Sundar RajMani Oral Abstract Presenter IndiaAssociate Professor in Nephrology, Christian Medical College, Vellore, India

SuceenaAlexander Oral Abstract Presenter IndiaChristian Medical College Vellore

Brahmkamal Hall - Plenary Hall